Praxis Precision Medicines, Inc.
vormatrigine
FOS & Generalized Epilepsy
Resolved
7days ago
Phase 3 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 3 trial results for vormatrigine in FOS & Generalized Epilepsy are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“POWER2, the second Phase 3 study for vormatrigine in FOS, is enrolling patients, with completion expected in the second half of 2026 and topline results anticipated in 2027.”